期刊
ANNUAL REVIEW OF IMMUNOLOGY, VOL 39
卷 39, 期 -, 页码 19-49出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-immunol-102119-073227
关键词
graft-versus-host disease; pathophysiology; prevention; therapy; regulation; tolerance
类别
资金
- National Institutes of Health (NIH): National Heart, Lung, and Blood Institute [R01 HL148164, 2R01 56067, R01 HL11879, HL095791, R01 HL133823]
- National Institute of Allergy and Infectious Diseases [R37 AI 34495, P01 AI 056299, U19 AI051731]
- National Cancer Institute [P01 CA142106, 2P01 065493, U01 CA244291]
- NIH/FDA [FD004099]
- American Society of Transplantation and Cellular Therapy New Investigator Award Grant
- Match Foundation Amy Strelzer Manasevit Research Program Grant
The study explores the pathophysiology of GVHD during allogeneic transplantation, including host/donor cell effectors, immune system and cytokine imbalance. It summarizes the translational application of these findings in designing novel therapies for GVHD prevention and treatment.
Worldwide, each year over 30,000 patients undergo an allogeneic hematopoietic stem cell transplantation with the intent to cure high-risk hematologic malignancy, immunodeficiency, metabolic disease, or a life-threatening bone marrow failure syndrome. Despite substantial advances in donor selection and conditioning regimens and greater availability of allograft sources, transplant recipients still endure the morbidity and mortality of graft-versus-host disease (GVHD). Herein, we identify key aspects of acute and chronic GVHD pathophysiology, including host/donor cell effectors, gut dysbiosis, immune system and cytokine imbalance, and the interface between inflammation and tissue fibrosis. In particular, we also summarize the translational application of this heightened understanding of immune dysregulation in the design of novel therapies to prevent and treat GVHD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据